Why the study?
Does ivabradine provide cardiovascular protection beyond heart rate reduction in experimental models?
Does ivabradine provide cardiovascular protection beyond heart rate reduction in experimental models?
Ivabradine exhibits pleiotropic cardiovascular protective effects in experimental models, some of which are independent of its heart rate-lowering action.
The bradycardic agent ivabradine has proved to be of benefit in experimental models with the end points of ischaemic myocardial blood flow and contractile function, infarct size, post‐infarct remodelling and atherosclerosis. The benefits to ischaemic myocardial blood flow and contractile function are strictly heart rate dependent; those on infarct size are partly heart rate independent. The heart rate dependency of ivabradine's benefit for atherosclerotic vascular function is contradictory, and that on post‐infarct remodelling is entirely unclear. British Journal of Pharmacology (2008) 155 , 970–971; doi: 10.1038/bjp.2008.347 ; published online 1 September 2008
No takes yet. Share an insight, caveat, or question.
Gerd Heusch (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: